Why Morepen Laboratories Share Price is Rising

India's pharmaceutical sector has witnessed robust growth, driven by factors such as increasing healthcare spending, a growing population, and a focus on generic drug manufacturing.

This growth has created opportunities for pharmaceutical companies to expand their operations and capture market share.

Morepen Laboratories is a leading pharmaceutical company in India. It is a key beneficiary of this expansion. The company specialises in a wide range of pharma products, including anti-infectives, cardiovascular drugs, and gastrointestinal medications.

This week, Morepen Labs is making headlines with its impressive stock performance. The company's share price has surged by 29.7% in the past five days, attracting investor attention. Read on to know about the factors driving the rally in Morepen Laboratories share price.

Strong Quarterly Results

In Q1FY25, the company's gross revenue increased to Rs 4.6 billion (bn), compared to Rs 4 bn in Q1FY24. This reflects a growth of 13.7%. The increase in revenue can be attributed to a strategic focus on high-value export markets, which led to a 31% growth in that segment.

Additionally, a decline in import prices has allowed the company to enhance its margins, further boosting overall revenue.

Net profit for the quarter rose significantly to Rs 361.7 million (m), up from Rs 146.3 m in Q1FY24, marking an impressive growth of 147.2%. The sharp increase in net profit is due to improved margins, driven by both increased revenue and a focus on cost-effective measures such as backward integration in the medical devices segment.

This strategic move has allowed the company to reduce expenses and improve profitability.

The gross margin contribution saw a substantial rise of 26%, primarily due to the revenue increase. Furthermore, the company's EBITDA for the current quarter surged by 93% to Rs 550.5 m, compared to the same period last year.

The focus on backward integration within the Medical Devices segment has not only contributed to cost savings but also strengthened the company's overall position in the market. By reducing dependency on external suppliers, the company has been able to control production costs and improve profit margins.

What Next?

Morepen Labs is strategically positioned to benefit from its recent fundraise, which was completed to support the rapid growth of the business. The company plans to significantly increase its manufacturing capacity for glucometers, blood pressure monitors, and other medical devices.

Glucometer production capacity is set to double from 2.5 m meters per annum to 5 m meters, while annual strip manufacturing capacity will rise from 500 m to 700 m strips.

Additionally, the production of blood pressure monitors will increase from 1.2 m to 2.5 m meters per annum. These expansions will be supported by full backward integration, including the addition of surface mount technology (SMT) machines at the Baddi facility.

On the pharmaceutical front, Morepen Labs is expanding its API (active pharmaceutical ingredient) capacity from 400 KL to 600 KL. This expansion aims to support the launch of new products, which will contribute to the company's growth.

The company's strategy focuses on repositioning itself as a leader in both the pharma and medical devices sectors.

The company plans to position itself as a reliable global partner for outsourcing, particularly in the China+1 model, where businesses look for alternatives to China for manufacturing.

Looking ahead, Morepen Labs is targeting revenue growth of 15-20% per annum. This growth will be driven by investments in new products, markets, and customer acquisition, both in India and globally.

The company is also focusing on improving its EBITDA margins by 3-4% through increased efficiencies and cost-effective operations. The growing customer base for glucometers is expected to lead to higher strip sales, further improving profitability.

With the Indian medical devices market expected to grow significantly, reaching US$ 50 bn by 2030 and US$ 250 bn by 2047, Morepen Labs is well-positioned to capitalize on this opportunity.

The global market for blood glucose testing and blood pressure devices is also projected to grow substantially, which presents additional growth prospects for the pharma company.

How Morepen Laboratories Share Price has Performed Recently

In the past five days, Morepen Laboratories share price has rallied 29.7%. In the last month, it is up 42%.

In 2024 so far, its share price has surged 59.5% and it has rallied 107.7% in the last one year.

The stock touched its 52-week high of Rs 80.2 on 22 August 2024 and a 52-week low of Rs 31.3 on 26 October 2023.

About Morepen Laboratories

Morepen Laboratories Limited is a pharmaceutical company. The Company is engaged in the business of manufacturing, producing, developing, and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also the home health products.

To know more about the company, check out Morepen Laboratories financial factsheet and its latest quarterly results.

For a sector overview, read our pharmaceuticals sector report.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Happy Investing.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...